Pritzlaff CA, Chang JC, Kuo SP, Tamura GS, Rubens CE, Nizet V: Ge

Pritzlaff CA, Chang JC, Kuo SP, Tamura GS, Rubens CE, Nizet V: Genetic basis for the beta-haemolytic/cytolytic activity of group B Streptococcus . Mol Microbiol 2001, 39:236–247.PubMedCrossRef 28. Doran KS, Chang JC, Benoit VM, Eckmann L, Nizet V: Group B streptococcal beta-hemolysin/cytolysin JQEZ5 cost promotes invasion of human lung epithelial cells and the release of interleukin-8.

J Infect Dis 2002, 185:196–203.PubMedCrossRef 29. Liu GY, Doran KS, Lawrence T, Turkson N, Puliti M, Tissi L, Nizet V: Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and GDC 973 carotenoid pigment function to subvert host phagocyte defense. Proc Natl Acad Sci U S A 2004, 101:14491–14496.PubMedCentralPubMedCrossRef 30. Baker JR, Pritchard DG: Action pattern and substrate specificity of the hyaluronan lyase from group B streptococci. Biochem J 2000,348(Pt 2):465–471.PubMedCrossRef 31.

Benchetrit LC, Fracalanzza SE, Peregrino H, Camelo AA, Sanches LA: Carriage of Streptococcus agalactiae in women and neonates and distribution of serological types: a study in Brazil. J Clin Microbiol 1982, 15:787–790.PubMedCentralPubMed 32. Haguenoer E, Baty G, Pourcel C, Lartigue MF, Domelier AS, Rosenau A, Quentin R, Mereghetti L, Lanotte P: A multi PI3K cancer locus variable number of tandem repeat analysis (MLVA) scheme for Streptococcus agalactiae genotyping. BMC Microbiol 2011, 11:171.PubMedCentralPubMedCrossRef 33. Radtke A, Lindstedt BA, Afset JE, Bergh K: Rapid multiple- locus variant-repeat assay (MLVA) for genotyping of Streptococcus agalactiae . J Clin Microbiol 2010, 48:2502–2508.PubMedCentralPubMedCrossRef 34. Uh Y, Kim HY, Jang IH, Hwang GY, Yoon KJ: Correlation of serotypes and genotypes of macrolide-resistant Streptococcus agalactiae . Yonsei Med J 2005, 46:480–483.PubMedCentralPubMedCrossRef 35. Rosini R, Rinaudo CD, Soriani M, Lauer P, Mora M, Maione D, Taddei A, Santi I, Ghezzo C, Brettoni

C, et al.: Identification of novel genomic islands coding for antigenic pilus -like MG-132 clinical trial structures in Streptococcus agalactiae . Mol Microbiol 2006, 61:126–141.PubMedCrossRef 36. Martins ER, Andreu A, Melo-Cristino J, Ramirez M: Distribution of Pilus islands in streptococcus agalactiae that cause human infections: Insights into evolution and implication for vaccine development. Clin Vaccine Immunol 2013, 20:313–316.PubMedCentralPubMedCrossRef 37. Forquin MP, Tazi A, Rosa-Fraile M, Poyart C, Trieu-Cuot P, Dramsi S: The putative glycosyltransferase-encoding gene cylJ and the group B Streptococcus (GBS)-specific gene cylK modulate hemolysin production and virulence of GBS. Infect Immun 2007, 75:2063–2066.PubMedCentralPubMedCrossRef 38. Merritt K, Jacobs NJ: Characterization and incidence of pigment production by human clinical group B streptococci. J Clin Microbiol 1978, 8:105–107.PubMedCentralPubMed 39. Milligan TW, Baker CJ, Straus DC, Mattingly SJ: Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci.

Comments are closed.